このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Sequana Medical マネジメント

マネジメント基準チェック /44

現在、CEO に関する十分な情報がありません。

主要情報

Ian Crosbie

最高経営責任者

€440.6k

報酬総額

CEO給与比率	96.5%
CEO在任期間	8.4yrs
CEOの所有権	n/a
経営陣の平均在職期間	5.2yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Sequana Medical の収益と比較して、Ian Crosbie の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	€441k	€425k	-€33m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€32m
Mar 31 2023	n/a	n/a	-€32m
Dec 31 2022	€464k	€449k	-€31m
Sep 30 2022	n/a	n/a	-€29m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€25m
Dec 31 2021	€417k	n/a	-€24m

報酬と市場: Ian の総報酬 ($USD 473.07K ) は、 German市場 ($USD 408.13K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Ian の報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ian Crosbie

8.4yrs

在職期間

€440,569

報酬

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ian Crosbie	CEO & Executive Director	8.4yrs	€440.57k	データなし
Kirsten Van Bockstaele	Chief Financial Officer	no data	€355.98k	データなし
Lies Vanneste	Director of Investor Relations	5.2yrs	データなし	データなし
Martijn Blom	Chief Commercial Officer	no data	データなし	データなし
Oliver Godje	Chief Medical Officer	4.1yrs	データなし	データなし

5.2yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: 2SEの経営陣は経験豊富で経験豊富です（平均在職期間は5.2年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ian Crosbie	CEO & Executive Director	5.3yrs	€440.57k	データなし
Erik Amble	Observer	1.8yrs	データなし	0.060% € 27.5k
Wim Ottevaere	Independent Non-Executive Director	5.3yrs	€52.50k	0.076% € 34.7k
James Udelson	Heart Failure Scientific Advisor	3.7yrs	データなし	データなし
Rudy Dekeyser	Non-Executive Director	no data	データなし	データなし
Maria Costanzo	Scientific Advisor	4.8yrs	データなし	データなし
Pierre Chauvineau	Independent Chairman	5.3yrs	€71.50k	0.025% € 11.6k
Javed Butler	Scientific Advisor	4.8yrs	データなし	データなし
Jeffrey Testani	Scientific Advisor	4.8yrs	データなし	データなし
W.H. Tang	Scientific Advisor	4.8yrs	データなし	データなし
Jackie Fielding	Independent Non-Executive Director	2.8yrs	€49.00k	データなし
G. Felker	Heart Failure Scientific Advisor	3.7yrs	データなし	データなし

4.8yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: 2SEの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Sequana Medical マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Sequana Medical NV, Annual General Meeting, May 23, 2024

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

High number of new directors

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Recent updates

Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024

New major risk - Shareholder dilution

Full year 2023 earnings released: €1.22 loss per share (vs €1.35 loss in FY 2022)

Sequana Medical NV to Report First Half, 2024 Results on Sep 19, 2024

Sequana Medical NV to Report First Half, 2024 Results on Sep 12, 2024

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure

No longer forecast to breakeven

New minor risk - Financial data availability

Sequana Medical NV has filed a Follow-on Equity Offering in the amount of €12 million.

New minor risk - Profitability

New major risk - Financial position

Sequana Medical NV, Annual General Meeting, May 23, 2024

Forecast to breakeven in 2026

New minor risk - Market cap size

Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

New major risk - Share price stability

Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome

Forecast to breakeven in 2024

First half 2023 earnings released: €0.65 loss per share (vs €0.68 loss in 1H 2022)

New major risk - Financial position

Sequana Medical NV to Report Q2, 2023 Results on Sep 14, 2023

Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure

Forecast to breakeven in 2024

Sequana Medical NV Announces Completion of 1,000th Alfapump Implant

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

Full year 2022 earnings released: €1.35 loss per share (vs €1.30 loss in FY 2021)

Full year 2022 earnings released: €1.35 loss per share (vs €1.30 loss in FY 2021)

Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure

Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON

High number of new directors

Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump

First half 2022 earnings released: €0.68 loss per share (vs €0.66 loss in 1H 2021)

Sequana Medical NV to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR

High number of new and inexperienced directors

Full year 2021 earnings released: €1.30 loss per share (vs €1.25 loss in FY 2020)

Sequana Medical Announces the Completion of Alfapump Implantations in Poseidon, the North American Pivotal Alfapump Study

Sequana Medical NV Receives Certification Under Mdr, the New European Medical Device Regulation

Sequana Medical NV Announces the Completion of Patient Enrolment in Poseidon, the North American Pivotal Alfapump Study

First half 2021 earnings released: €0.66 loss per share (vs €0.62 loss in 1H 2020)

Independent Non-Executive Director Jason Hannon has left the company

Sequana Medical’s Results from RED DESERT Alfapump DSR® Study Presented as One of the Highlights At Heart Failure 2021 Online Congress

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44